Compare PDC & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDC | CMMB |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Japan | Israel |
| Employees | 20 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 13.2M |
| IPO Year | N/A | 2023 |
| Metric | PDC | CMMB |
|---|---|---|
| Price | $4.96 | $1.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 26.4K | ★ 46.0K |
| Earning Date | 07-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $39.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $0.87 |
| 52 Week High | $7.80 | $3.86 |
| Indicator | PDC | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 43.38 |
| Support Level | $4.48 | $1.48 |
| Resistance Level | $5.56 | $1.64 |
| Average True Range (ATR) | 0.37 | 0.19 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 25.53 | 16.02 |
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.